LONDON (Alliance News) - E-Therapeutics PLC said Thursday it expects "another exciting year", and said it will provide a more complete summary of its various projects at the end of the first half.
In a statement ahead of its annual general meeting the company highlighted progress in its pipeline over the last year, particularly with its discovery platform.
It added that its Phase Ib study into ETS2101 in pancreatic and hepatocellular cancer has begun since it issued its full-year results, and the last patient in its Phase Ia trial in brain cancer in the US has now been enrolled.
"With the progress we are making both in the clinical programmes and in discovery, we expect another exciting year for the company," Chief Executive and Chairman Malcolm Young said in the statement.
Shares in E-Therapeutics are trading up 2.5% at 41.00 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
